Neglected Diseases R&D Financing Proposals Shaping Up At WHO 14/07/2011 by Intellectual Property Watch Leave a Comment Global public health experts in charge of exploring ways to finance R&D on diseases endemic in developing countries last week provided a preliminary summary of assessments on proposals provided by various stakeholders. They also made recommendations to establish global mechanisms, including a binding global instrument for R&D and innovation for health.
WHO Enters Next Phase Of Global Plan To Increase Flu Vaccine Production 14/07/2011 by Catherine Saez, Intellectual Property Watch 1 Comment The World Health Organization will be entering a new phase of its global action plan for influenza vaccines, a WHO representative told reporters today. The goals of the first phase of the programme should be furthered but with more attention given to the local health and policy environment, WHO said.
WIPO, The ‘Sleeping Beauty’ Of Climate Change Policy, Urged To Awaken 14/07/2011 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Intellectual Property Organization has taken its first public steps in the climate change debate by holding a conference on the subject this week. The organisation’s expertise in intellectual property policy and technology transfer is being sought by several other actors in the field, in particular the United Nations climate change agency.
Does Introduction Of A Utility Model Protection Regime Make Sense In India? 13/07/2011 by Intellectual Property Watch 2 Comments India has at least seven diverse intellectual property (IP) legislations related to protection already in place. Its focus should therefore arguably be directed – along the lines of many other IP jurisdictions – on more stringent enforcement modus operandi of the IP rights. Is there scope for introducing yet another IP legislation – the utility model protection law – in the Indian IP landscape and if so, what should be its scope and implication, asks Swarup Kumar.
Medicines Patent Pool Boosts HIV Drug Prospects With First Licence 12/07/2011 by William New, Intellectual Property Watch 4 Comments The Medicines Patent Pool and pharmaceutical company Gilead Sciences today announced a breakthrough licence agreement to allow for the production of key HIV medicines at lower cost and in an easier-to-use formulation, making them more accessible to developing countries. The agreement also opens up the use of treatments for Hepatitis B for the first time.
WIPO Ventures Into Global Debate On Climate Change 08/07/2011 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Intellectual Property Organization is continuing its push to become involved in some of the biggest policy questions of the day with an international conference on climate change next week. This follows recent efforts on public health and food security.
UN Body Addresses Problems With IP Rights Within Europe 08/07/2011 by Intellectual Property Watch 3 Comments The United Nations Economic Commission for Europe (UNECE) is holding a two-day meeting to increase awareness of intellectual property rights throughout the region.
Non-Communicable Diseases Issue Energises Public Health Policymakers 07/07/2011 by William New, Intellectual Property Watch Leave a Comment Concern over non-communicable diseases – traditionally a more developed-country set of problems like diabetes – is energising the international public health policy community. But representatives of the public interest are still grappling with their response.
CERN Issues Open Hardware Licence For Electronic Designs 07/07/2011 by Intellectual Property Watch 1 Comment The European Organisaton for Nuclear Research (CERN) today issued an open hardware licence for electronic designs, following its principle of “open science.”
WHO Expert Group Sifts Ideas For A New Global Drug R&D Mechanism 05/07/2011 by William New, Intellectual Property Watch 1 Comment A diverse team of global experts on public health research and development will meet this week behind closed doors to analyse proposals for ways to fund R&D on diseases afflicting poor populations – and for who should coordinate such global efforts.